Soybean oil emulsion administration during parenteral nutrition in the preterm infant: effect on essential fatty acid, lipid, and glucose metabolism.
To examine the effect of a soybean oil emulsion on essential fatty acid, lipid, and glucose metabolism, preterm infants were randomized to receive 0.5 g/kg/d lipid for 5 days (n = 10, group 1) or 0.5 increased to 2.0 g/kg/d over 5 days (n = 11, group 2). Triene/tetraene ratios did not change in group 1, but decreased in group 2. In both groups, plasma phospholipid linoleate (percent and micrograms per milliliter) increased, the increase being greater in group 2. In both groups, percent content of arachidonate and 5,8,11-eicosatrienoate decreased, and that of oleate remained unchanged. In contrast, absolute content of arachidonate and oleate tended to increase, and that of 5,8,11-eicosatrienoate remained unchanged. At a lipid intake of 0.5 g/kg/d, no infants had hyperlipemia. When lipid intake exceeded 1.0 g/kg/d, the frequency of hypertriglyceridemia (triglycerides greater than 200 mg/dL) and free fatty acidemia, with the free fatty acid/molar albumin ratio exceeding 6:1, increased. Plasma glycerol increased slightly, but was substantially less than the rise in enzymatically determined triglycerides. Hyperglycemia was self-limiting and did not require alteration in dextrose intake. Thus, (1) infusion of a soybean oil emulsion at 0.5 to 2.0 g/kg/d maintains essential fatty acid status and phospholipid arachidonate concentrations; (2) significant hyperlipemia occurs when lipid intake exceeds 1.0 g/kg/d; (3) hyperglycemia associated with lipid infusion tends to be self-limiting and may not require alteration in lipid or dextrose intake; and (4) enzymatically determined triglycerides may be used to monitor lipid tolerance, provided that allowance is made for a small but systematic overestimation resulting from the rise in plasma glycerol.
D015126:8,11,14-Eicosatrienoic Acid / Q000097:blood / Q000031:analogs & derivatives; D000704:Analysis of Variance; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000097:blood; D005217:Fat Emulsions, Intravenous; D005228:Fatty Acids, Essential / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000378:metabolism; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000097:blood; D050356:Lipid Metabolism; D019301:Oleic Acid; D009829:Oleic Acids / Q000097:blood; D010289:Parenteral Nutrition, Total; D010743:Phospholipids / Q000097:blood; D010938:Plant Oils / Q000008:administration & dosage*; D012044:Regression Analysis; D013024:Soybean Oil / Q000008:administration & dosage*; D014280:Triglycerides / Q000097:blood
D001095:Arachidonic Acids; D005217:Fat Emulsions, Intravenous; D005228:Fatty Acids, Essential; D005230:Fatty Acids, Nonesterified; D008041:Linoleic Acids; D009829:Oleic Acids; D010743:Phospholipids; D010938:Plant Oils; D014280:Triglycerides; D016718:Arachidonic Acid; D019301:Oleic Acid; D013024:Soybean Oil; D019787:Linoleic Acid; D015126:8,11,14-Eicosatrienoic Acid; D005947:Glucose; C010944:mead acid